Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Learn how Us Market Index Funds Retirement 2024 provides core exposure to the U.S. market. Compare funds and refine your retirement allocation.
28,197 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Navitas NVTS and ON Semiconductor are capturing attention as AI data-center demand climbs. Analysts see a potential r...
In his first week as Disney’s leader, Josh D’Amaro confronts three major headwinds that could set the tone for his te...
Gas costs have surged amid renewed Middle East tensions, with drivers now paying more than before. Analysts warn vola...
Timken stands at a pivotal moment as it reports Q1 2026 earnings. This guide breaks down the business mix, growth dri...
Disney beats Q2 expectations, sending Wall Street into a target-upgrade cycle. JPMorgan, Barclays and Guggenheim lift...
When Oshkosh released its latest results, the focus quickly shifted to a sharp stock move. This guide explains what h...
AMD’s latest earnings call highlights a rapid AI-led growth wave and a massive server CPU opportunity. Here are the f...
Bright MLS unveils Bright Promote, an integrated advertising tool that lets agents launch digital and mail campaigns ...
When bad news hits a stock, investors ask if it’s a bargain. This piece weighs UPS’s challenges against its resilient...
Two retail giants, two distinct models. This guide breaks down Walmart Costco Wholesale: Which stock earns a spot in ...
Tesla sits around $445 as Q1 margin gains meet AI roadmap momentum, prompting fresh Buy, Sell or Hold questions for i...